FDA's Foreign Inspections of Drug Manufacturers Have Not Rebounded to Pre-Pandemic Levels
Wednesday, November 13, 2024
FDA's Foreign Inspections of Drug Manufacturers Have Not Rebounded to Pre-Pandemic Levels
The Food and Drug Administration (FDA) inspects drug manufacturers here and overseas to ensure the safety and quality of drug sold in the United States. But FDA paused many of its in-person inspection efforts during COVID-19 because of travel disruptions and safety concerns. So now that COVID is over, are inspections back to normal? GAO's Mary Denigan-Macauley tells us more.
